D. E. Shaw & Co., Inc. Pyxis Oncology, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $125 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PYXS
# of Institutions
71Shares Held
22.5MCall Options Held
0Put Options Held
0-
Laurion Capital Management LP New York, NY3.63MShares$12.9 Million0.07% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.54MShares$12.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$9.92 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.5MShares$8.9 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$7.65 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $125M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...